SwingTrade Member Forum

[Rawnoc]

REPR--Sales +40% net income up 203% EPS +.005

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7657367

MY ANALYSIS OF THIS PAST Q PLUS FORWARD PREDICTION:

(1) Freedom60 Sales up 43%, most revenue is an increasing recurring revenue stream as Hizentra and Vivaglobin patients tend to be patients for life who require REPR's tubing sets every month which run $300 per quarter per patient which is growing steadily as Hizentra sales continue to grow. 10Q forecasts further increases as a result of Hizentra drug approval last year and the Freedom60 now used for other drugs as well.

(2) I calculate is that they sold around 1200/1300 Freedom60 devices in the Q bringing the total in operation to around 11,500 with a recurring revenue stream of now $880,000 per Q. The recurring revenue stream now going forward is higher than any other quarter prior to this quarter in total Freedom60-related sales and this growing recurring revenue stream is now more than 70% of sales.

(3) Sequential sales +16%, gross profit +18%, operating profit +59%, net income +66%. There will likely having a decline in SG&A expenses despite an increase in sales because I see no trade shows listed going forward plus a mechanical engineer and two sales associates were hired only temporarily.

PREDICTION....

(my prediction/analysis of last Q was virtually spot on)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=55617265
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58813499

REQ-Q-VAC sales of $250,000
FREEDOM60 sales of $1.15 million
Total sales expectation = $1.4 million

Gross profit margin of 70% = 980,000
Other operating Expenses = $450,000
Operating Profit = $530,000
Income Taxes = $218,000
After-tax net income of $312,000
After-tax EPS of +.01
Current PE of 3-4 for a share price .12/.16.
PE of 15 = .60/share target.
With EPS of +.02/+.03 in future Qs in 2011, then target becomes $1.20/$1.80

All of the above just my opinion.